Cloud practice management, EHR and medical billing software for independent practices
PracticeSuite sells an all-in-one cloud suite covering practice management, EHR, billing and patient engagement to independent practices and billing companies. Its stack pairs AWS with Oracle, VMware and Proxmox, and job posts point to standing up an SRE function and building CI/CD on AWS, which reads as a push to modernize legacy infrastructure. HL7, FHIR, Mirth Connect and Rhapsody show that healthcare interface reliability is a core engineering concern.
PracticeSuite, Inc. is a privately held healthcare software company founded in 2004 and headquartered in Tampa, Florida. Its cloud platform combines practice management, electronic health records, medical billing, patient engagement and practice marketing. Customers range from solo practices and multi-specialty groups to medical billing firms, technology resellers and other software vendors across the United States. The company employs 501–1,000 people and hires in the United States and India.
PracticeSuite runs on AWS (RDS, CloudWatch) alongside Oracle, Java, Python, VMware and Proxmox. It uses HL7, FHIR, Mirth Connect and Rhapsody for interoperability, plus Salesforce, HubSpot and Power BI.
Yes. Engineering is the largest share of PracticeSuite's hiring, which is accelerating. Job posts focus on SRE, AWS infrastructure, CI/CD and healthcare interface development, with roles in the United States and India.
PracticeSuite is headquartered in Tampa, Florida. The privately held company was founded in 2004 and has 501–1,000 employees.
Other companies in the same industry, closest in size
PracticeSuite, Inc.'s technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.